Eli Lilly and Company (NYSE:LLY) Shares Bought by Strategic Planning Group LLC

Strategic Planning Group LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 9.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,471 shares of the company's stock after buying an additional 632 shares during the period. Eli Lilly and Company comprises 1.2% of Strategic Planning Group LLC's investment portfolio, making the stock its 25th biggest holding. Strategic Planning Group LLC's holdings in Eli Lilly and Company were worth $6,171,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the business. FPC Investment Advisory Inc. grew its stake in shares of Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the period. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $43,000. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $48,000. Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $50,000. Finally, Capital A Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $63,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LLY. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, May 30th. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their target price for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Trading Down 0.1%

LLY traded down $0.71 during trading on Thursday, hitting $765.13. The company's stock had a trading volume of 3,632,853 shares, compared to its average volume of 3,644,545. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock has a market cap of $725.14 billion, a PE ratio of 65.34, a PEG ratio of 1.40 and a beta of 0.48. The firm's 50 day moving average price is $772.75 and its 200-day moving average price is $799.41. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the previous year, the company posted $2.58 earnings per share. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.